Oral drugs gain on injectables in multiple sclerosis market, study finds
BURLINGTON, Mass. — Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.
Healthcare industry research firm Decision Resources found that injected disease-modifying drugs for MS, such as Teva’s Copaxone (glatiramer acetate) and biotech drugs called interferon-betas, had a 70% share of the patient market in the second quarter of 2013, compared with 80% during the same period in 2012. A new drug made by Biogen Idec, Tecfidera, also captured a large portion of the patient population. Still, injectables captured 84% of patients undergoing first-line treatment.
"U.S. claims data confirm that time-tested injectables remain a core component of new MS treatment, overall and in treatment-naive patients, likely due in part to neurologists’ conservative adoption of new agents," Decision Resources senior director Jonathan Searles said. "That said, with oral DMTs capturing nearly 18% total patient share in the second quarter among patients in our sample who were recently treated, and with the use of Tecfidera surging, we anticipate continued steady losses among current mainstays over the near term."
CVS Caremark report: Annual specialty Rx spend to quadruple by 2020
WOONSOCKET, R.I. — Specialty drug spend is expected to more than quadruple by 2020, reaching approximately $402 billion a year, according to a new CVS Caremark report released today.
The Insights report on specialty pharmacy prescribing trends and strategies for managing costs also reports that while only a very small percentage of patients (less than 4%) use specialty medications, they account for 25% of health care costs. Specialty drugs treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer and represent a rapidly growing area of spending in health care.
"Specialty pharmacy trend is driven by price, mix and utilization, just like traditional drug trend, but managing specialty drug trend is more complex," Jon Roberts, president of CVS Caremark’s PBM business said. "While many payors already have basic strategies in place to manage costs and ensure safe and effective use of specialty drugs, we have found that every plan has the opportunity to improve upon their management of this category."
The report reviews foundational strategies for managing specialty drug trend and provides additional insights into key areas where CVS Caremark offers expanded services to improve cost savings for clients. These areas include: Understanding the cost impact resulting from the location of drug administration for infused drugs (e.g., at the hospital, doctor’s office or at home), gaining visibility to the portion of specialty pharmacy spend billed under the medical benefit, and providing a full range of services designed to provide comprehensive care for the patient that can improve outcomes and reduce overall medical costs.
"Clinical appropriateness is the primary consideration when managing specialty pharmacy patients, but there are a variety of other factors that can also affect the optimal therapy choice for an individual," Alan Lotvin, EVP of specialty pharmacy at CVS Caremark said. "For example, the site of care where an infused drug is administered to the patient is one area that can significantly impact costs for the patient and payor without necessarily influencing the patient’s outcomes."
Understanding the Cost Impact of Site of Care
Many specialty drugs for the treatment of conditions such as cancer, rheumatoid arthritis and multiple sclerosis are administered via infusion that can take place in a hospital, physician’s office, infusion center or even the patient’s home. Costs for both the drug and its administration can vary by thousands of dollars depending on where the patient receives the infusion. CVS Caremark noted that it offers programs that can help payors increase the utilization of more cost-effective sites of care for infused therapies.
Spanning the Pharmacy and Medical Benefit
Nearly half of specialty drug spend actually occurs under the medical benefit rather than the pharmacy benefit, where it can be harder to track and manage using clinical and cost management strategies. CVS Caremark stated that it offers clients management techniques to help capture and control spend billed under the medical benefit.
Providing Comprehensive Whole-Patient Care
Compared with the average patient, specialty patients are more likely to have multiple diagnoses, see more specialists, fill more prescriptions and have more lab tests, ER visits and hospitalizations. As a result, specialty patients have much higher overall medical costs, as much as 8.5 times higher than non-specialty patients. CVS Caremark provides a range of services designed to address these needs and help streamline care management for both the patients and their physicians in order to help improve health outcomes and avoid unnecessary costs for patients and payors. Services include:
- New program to be rolled out in 2014 that will enable specialty pharmacy patients to access our full suite of specialty pharmacy services through their local CVS/pharmacy store. The patient’s local CVS pharmacist can accept their prescription and connect them with the support services available through the CVS Caremark specialty pharmacy
- Care provided by CVS Caremark therapy-specific Specialty CareTeams who work with the patient to monitor outcomes and side effects, encourage medication adherence, and assist with refills, prior authorizations and benefit verification.
- Complete patient management available through a care management program for rare diseases. Care management nurses help patients manage non-pharmacy issues related to their condition in coordination with the patient’s health care provider and the CVS Caremark CareTeam.
To access the full 2013 Specialty Trend Management Insights Report in the publication section click here.
Spending on drugs in the United States expected to grow again next year after falling
NEW YORK — Global spending on drugs will pass the $1 trillion mark next year, according to a new study by the IMS Institute for Healthcare Informatics, a division of healthcare market analysis firm IMS Health.
The report, "The Global Use of Medicines: Outlook through 2017," released Tuesday, forecasts $1.2 billion in sales four years from now. The report covers the United States, Japan, China and the top five markets in the European Union.
The United States, according to the report, will see resumed increases in spending on drugs next year, after seeing reductions in spending over the past couple of years, as access to health care expands and the number of expirations of branded drug patents taper off.
In developed markets, numerous specialty drug classes — for such conditions as cancer, autoimmune diseases, respiratory diseases, immune system disorders, chronic viral infections and organ transplants — will see strong spending in 2017, particularly cancer drugs, which will have sales of $74-84 billion. Among primary-care drugs, diabetes drugs are at the top, with expected sales of $34-39 billion.
Overall, the United States will account for 31% of spending on drugs in 2017, compared with 34% last year.